News | June 15, 2021
Zydus Cadila receives tentative USFDA approval for Brivaracetam
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Subscribe To Our Newsletter & Stay Updated
